1. Merck CEO Frazier says COVID vaccine hype a 'grave disservice' to the public — Why Inovio is the front runner in COVID vaccine development — Biogen and Eisai trial drug in asymptomatic Alzheimer's — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Please take our quick survey on how COVID-19 is impacting your job It will only take a minute or two to respond. The survey is confidential, and does not require registration. Thank you in advance for your participation. We will provide regular updates on results as responses accumulate.
    Dismiss Notice

Sales Expansion

Discussion in 'Braeburn Pharmaceuticals' started by anonymous, Nov 28, 2017 at 10:13 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Anyone have any details on the sales expansion? Salary range, benefits, culture, etc.? Good move or a risk? Final interview details?
     

  2. anonymous

    anonymous Guest

    The drug dose is too low to work. This company is famous for screw ups.
     
  3. anonymous

    anonymous Guest

    Suboxone people just got approval for same sub Q Bup ... Billion dollar will crush you... no chance for success
     
  4. anonymous

    anonymous Guest

    Derkass has a horrible reputation for screwing up and blaming others.
     
  5. anonymous

    anonymous Guest

    Any offers yet??? Start date??
     
  6. anonymous

    anonymous Guest

    Base is 110-120k
    Auto 1500 Month
    Bonus 45-60k @ plan is uncapped
    FDA votes 1/19/18
     
  7. anonymous

    anonymous Guest

    Has anyone successfully negotiated a sign on bonus? (You know, those of us that usually get a fifth payout)
     
  8. anonymous

    anonymous Guest

    Some advice for “those of you who are used to your fifth payout”:

    Don’t do it. I fell for the big pay and the Braeburn vision too and then ended up with nothing. You think you are miserable at Indivior because of what? They don’t have anywhere NEAR the problems of big pharma and they are not a startup, a hybrid of a company that these biotechs are striving to be! Take a look at the success rate for start ups in the past 10 years and decide if it’s really worth it to take this risk. Big pay=Big risk
     
  9. anonymous

    anonymous Guest

    Judging by the comments on their board, one would think it's the worst company out there. But go to any pharma company board and you'll see the exact same bitching. I didn't jump for this company bc they have a shitty track record in the short time they've been around, and they're nowhere near as financially solvent as Indivior is. Have they EVER turned a profit? Indivior already has the jump on them, with a product that appears clinically superior, at least on paper. CAM's doses are low for the monthly, and a weekly injectable seems like more trouble than it's worth for offices. Some went for the payday, and I have a feeling they'll regret it. Indivior, for all its faults, still has over a decade of experience in this market and did their homework with their new injectable. As AP stated, Indivior isn't big pharma in terms of overhead and staff so they can absorb some revenue loss without slashing sales force. And they're in a much better financial position than Braeburn. This isn't an Indivior homer talking, but someone who is looking at both companies as objectively as possible. And you can't discount the brand recognition either, naming their product something similar to Suboxone will help. Managed care will determine a lot, but again I don't trust a start up over a company with years of relationships in this area.
     
  10. anonymous

    anonymous Guest

     
  11. anonymous

    anonymous Guest

    Have they made offers yet? I haven’t heard of any Indivior people leaving since Utah and SoCal.
     
  12. anonymous

    anonymous Guest

    UT not his choice. Nothing from SoCal yet.
     
  13. anonymous

    anonymous Guest

    There will be plenty to leave but none that will be missed. When u chase a little money in the short term u lose in the long run. This company has yet to have a month making money. How long until the money runs out. There’s no evidence they are even going to get approval. Just too much risk for an unproven company. And their hiring tactics were so grimy and underhanded. They made it obvious they were little brother and they knew it. They are trying to over pay for relationships they don’t have but how long can they do that? Bad business
     
  14. anonymous

    anonymous Guest

    company is taking cheap way out! They don't want to pay good reps but will try to retread old ones or buy what they think are ones with relationship. Trust me call the ones w/buy and bill experience and it will be a better decision than the direction we've turned. Let's stop being 2nd rate and make necessary changes to succeed!
     
  15. anonymous

    anonymous Guest

    How will we be able to find out about the approval?
     
  16. anonymous

    anonymous Guest

    any news?
     
  17. anonymous

    anonymous Guest

    No news of approval-did the FDA reject it? Now what????
     
  18. anonymous

    anonymous Guest

    No news is bad news. Haha haha!
     
  19. anonymous

    anonymous Guest

    Why haven't we heard anything yet? It's the 20th?
     
  20. anonymous

    anonymous Guest

    FDA is part of govt shut down